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Abstract 
The purpose of this review article is to give an overview of atopic dermatitis in companion animals and of recent 
developments including knowledge on immunological background, novel treatment options and difficulties in 
disease management. The prevalence of hypersensitivities seems to be increasing. The pathogenetic mechanisms 
are not fully understood, yet multiple gene abnormalities and altered immunological processes are involved. In dogs 
and cats, the diagnosis of atopic dermatitis is based on history, clinical examination and exclusion of other differen-
tial diagnoses. Intradermal testing or testing for serum allergen-specific Immunoglobulin E is only used to identify 
allergens for inclusion in the extract for allergen immunotherapy. Symptomatic therapy includes glucocorticoids, 
ciclosporin, essential fatty acids and antihistamines. A selective janus kinase 1 inhibitor and a caninized monoclonal 
interleukin-31 antibody are the newest options for symptomatic treatment, although longterm effects still need to be 
assessed. The chronic and often severe nature of the disease, the costly diagnostic workup, frequent clinical flares and 
lifelong treatment are challenging for owners, pets and veterinarians. Patience and excellent communication skills are 
needed to achieve a good owner compliance and satisfactory clinical outcome for the animal.
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Background
Atopic dermatitis (AD) is a common skin disease in 
dogs and cats. Its clinical, immunological, histological 
and pathological features in dogs are so similar to the 
human counterpart, that canine atopic dermatitis has 
been suggested as an animal model for human AD [1, 
2]. In Table 1 some of the similarities and differences are 
summarized. Much less is known on the pathogenesis in 
cats, but the clinical findings are different to those seen in 
humans and dogs.
Canine atopic dermatitis
Canine AD is a multifactorial disease process. It is 
defined as a “genetically predisposed inflammatory and 
pruritic allergic skin disease often associated with a pro-
duction of immunoglobulin (Ig) E against environmental 
allergens” [3]. The estimated prevalence of AD in the dog 
is approximately 10–15% [4]. Although the pathogen-
esis is not completely understood, there is evidence for 
genetic abnormalities, an altered immune system with 
cutaneous inflammation and a skin barrier defect [5, 6].
Genetic background
Multiple gene expressions involved in skin barrier func-
tion and cutaneous inflammation have been described 
as down- or upregulated in the skin of privately owned 
atopic dogs [7–9] as well as in a canine model of AD [10]. 
In the latter study, 361 genes relevant for inflammation, 
wound healing or immune response processes showed 
an increased expression, whereas 226 genes associated 
with differentiation and skin barrier function showed 
decreased mRNA concentrations in allergen-treated skin 
of sensitized dogs [10]. In atopic German shepherds a 
significant association with chromosome 27 was deter-
mined, especially with genes that had a connection to 
plakophilin 2 production [11]. Plakophilin 2 is an impor-
tant structural protein, which is expressed in epithelial 
and immune cells [11, 12]. The predisposition of Ger-
man shepherds for AD is likely due to a risk haplotype 
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in combination with multiple variants resulting in a 
changed expression of the plakophilin 2 gene and nearby 
genes [11]. In the United Kingdom the risk of Labrador 
and Golden retrievers to develop AD was almost 50% 
due to the genetic background [13, 14]. Multiple breeds 
including Boxer, Westhighland White Terrier, French 
bulldog, Bullterrier, American cocker spaniel, English 
springer spaniel, Poodle, Chinese Sharpei, Dachshund, 
Collie, Miniature schnauzer, Lhasa apso, Pug and Rho-
desian ridgeback are also predisposed [15, 16] and breed 
predispositions vary with geographic location [17].
Immunologic alterations
In acute lesions, allergic inflammation triggers the release 
of cytokines such as interleukin (IL-) 4 and IL-13, which 
induce a T helper 2 (Th2) response [1, 18, 19]. In more 
chronic skin lesions, CD4+ and CD8+ skin-associated 
T lymphocytes additionally stimulate the production of 
various cytokines such as IL-13, IL-22 and IFN-γ [20]. 
Recent findings on cytokines and specific cell types in 
atopic dogs are listed in Table 2.
Skin barrier defects
According to the “outside-in” theory an impaired epider-
mis leads to an increased allergen penetration and hence 
a higher allergen exposure of epidermal immune cells 
[21]. This skin barrier defect may be due to decreased 
filaggrin concentrations [22]. Caspase 14 is involved in 
the breakdown of filaggrin into natural moisturizing 
factors such as free amino acids and small peptides and 
altered concentrations might influence the skin barrier 
function and hydration of the stratum corneum [23, 24]. 
Conflicting results regarding the filaggrin metabolism 
in atopic dogs have been published with lower [22] and 
higher caspase 14 concentrations [24]. Changes in the 
ceramide composition of lesional canine atopic skin have 
been described [25, 26] contributing to disorganisation of 
the lipid envelope and hence disruption of the epidermal 
barrier. Ceramide profiles of atopic dog skin contained 
Table 1 Similarities and differences of AD in dogs and humans
Dogs Humans
Pathogenesis Th2 immune response
Skin barrier damage
Allergic inflammation
[18, 19, 153]
Th2 immune response
Skin barrier damage
Allergic inflammation
[154]
IL-4 and IL-13 Pruritus, acute inflammation [155] Pruritus, acute inflammation [156, 157]
Periostin (PO) expression Increased expression, related to the chronicity of skin lesions 
[158]
Increased expression, related to the chronicity of skin lesions 
[159, 160]
Histologic pattern Spongiotic, hyperplastic dermatitis with mononuclear infil-
trate; predominantely T-lymphocytes [153, 161]
Spongiotic, hyperplastic dermatitis with mononuclear infil-
trate; predominantely T-lymphocytes [162, 163]
Dysbiosis Reduced microbiome diversity [164] and fungal dysbiosis 
[165]
Reduced microbiome diversity and fungal dysbiosis [166]
Clinical signs Eczematous skin lesions with no progression of clinical signs 
e.g. no development of asthma [2, 44]
Atopic march
Allergy testing Intradermal testing without high risk of anaphylactic reac-
tions [69]
Skin prick testing
Immunotherapy Accelerated immunotherapy without increased risk for 
anaphylactic reactions [76, 78, 79]
Standard AIT
Table 2 Recent findings on T cells and cytokines in canine atopic dermatitis
Cytokine/cell Function
IL-31 Important role in atopic pruritus [167]. Its serum concentration correlates with the severity of active skin lesions [168]
IL-13 Induces production of PO in keratinocytes and fibroblasts, associated with chronicity of skin lesions and their deterioration 
[1]
IL-25 Increased in PO-stimulated keratinocytes [1], clinical relevance unclear. In a murine asthma model relevant for Th2-medi-
ated immunity, contributes to a decreased epidermal barrier function in human AD [169–171]
IL-33 Upregulated in chronic lesional skin, similar to atopic humans [172]
CD 34+ cells Increase in peripheral blood, unclear clinical relevance [173]
CD4+ CD25+ FoxP3+ cells Significantly higher percentage in peripheral blood and correlated with severity of AD [174]
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lower amounts of CER [EOS], CER [EOP] and CER [NP] 
[27], similar to what is seen in humans. A decreased 
relative content of ceramides in atopic dogs might be 
one reason for the increased transepithelial water loss 
observed in both lesional and non-lesional skin [28]. 
Moreover, house dust mite allergens can alter the expres-
sion and possibly also the function of corneodesmosomal 
and tight junction proteins through proteolytic digestion 
and/or allergic inflammation, facilitating a higher aller-
gen penetration through the epidermis [29].
Feline atopy‑like dermatitis
The function of IgE in the cat is not completely clarified, 
consequently the term “feline atopic dermatitis” is not 
ideal [30, 31], but rather it is refered to as “feline atopy-
like dermatitis”. The pathogenesis of feline atopy-like 
dermatitis is not completely elucidated. Data on genetic 
alterations and skin barrier abnormalities as reported in 
human and canine AD are rare.
Genetic background
In a large study evaluating allergic cats, pure-bred cats 
were overrepresented in the group of cats with atopy-
like dermatitis compared to cats with flea allergy, but the 
study lacked a non-allergic control group [32]. In this 
study, Abyssinians were only affected by atopy-like der-
matitis and not flea allergy. A predisposition for Devon 
rex, Abyssinian and domestic shorthaired cats was 
reported in another study [33]. A case report of three lit-
termates with clinical signs and history consistent with 
atopy was described implying a heritable factor [34], 
however more detailed genetic studies are lacking [31].
Immunologic and skin barrier alterations
In cats, histopathologic features of atopy-like dermatitis 
include perivascular to diffuse dermal infiltration of T 
lymphocytes, activated antigen presenting cells, eosino-
phils, macrophages and high numbers of mast cells [35]. 
A significant increase of CD4+ T cells, IL-4 and CD1a+ 
dentritic cells was found in the skin of cats with atopy-
like dermatitis, pointing to a Th2-mediated immune dys-
function [33, 36], although cytokine pathways have not 
been investigated [37]. Comparable to humans and dogs 
[38] a fungal dysbiosis was found with next generation 
sequencing of skin swabs taken from healthy and allergic 
cats [39]. Skin hydration as a measure of the skin barrier 
did not always correlate with clinical scoring indicating 
that a barrier defect may not be as relevant in cats [40].
Practical approach
Clinical features
The following three main allergy categories can be dis-
tinguished in cats and dogs: flea (and other insect bite) 
hypersensitivities, cutaneous adverse food reaction (AFR) 
and AD due to environmental allergens. The clinical signs 
in the atopic dog are mostly distinct when compared to 
the atopic cat. A short overview of the main clinical fea-
tures, diagnosis and treatment options in companion ani-
mals is given in Table 3.
Clinical features of canine AD
In dogs, clinical signs of an environmental allergy mainly 
develop between 6 months and 3 years of age [41]. Ery-
thema is a primary lesion of canine AD; pruritus and 
inflammation can result in self-induced alopecia, excoria-
tion and secondary infections with papules, pustules and 
crusts [41, 42]. Axillae, ventral abdomen, distal extremi-
ties, inner pinnae and periocular, perioral and perianal 
regions are commonly affected [42]. Otitis externa is pre-
sent in half of the dogs with AD. Predilection sites dif-
fer from breed to breed [43]. Even though dogs can have 
multiple target organs for hypersensitivities (including 
gut and respiratory) [44], the contact with environmen-
tal allergens predominantly induces skin lesions in this 
species [45]. There is no evidence for the progression of 
initially exclusive cutaneous lesions to respiratory signs 
and systemic hypersensitivities comparable to the “atopic 
march” in humans [44]. In contrast to the cat, clinical 
examination in the dog frequently provides clues on the 
pathogenesis of the pruritus as to the presence of flea bite 
hypersensitivity versus environmentally-induced atopy 
or AFR. The former is characterized by pruritus focused 
on the dorsal lumbosacral area, ventral abdomen, tailbase 
and thighs.
Clinical features of feline atopy‑like dermatitis
The manifestation of specific cutaneous reaction patterns 
[46] can indicate an allergic primary cause in cats. These 
involve head and neck pruritus, miliary dermatitis char-
acterised by small crusted papules, self-induced alopecia 
without any other clinical lesions and eosinophilic lesions 
such as eosinophilic indolent ulcers, eosinophilic granu-
lomas and eosinophilic plaques [32, 47]. In rare cases, 
untypical AD symptoms such as plasma-cell pododerma-
titis, seborrhoea, ceruminous otitis, facial erythema and 
exfoliative dermatitis were reported [31, 48]. Additionally 
noncutaneous signs such as sneezing, coughing, conjunc-
tivitis, diarrhoea or vomiting can be presented in affected 
cats [32]. The disease onset can vary, but commonly it is 
under 3 years [31, 32], whereas the mean age for AFR is 
slightly higher (approximately 4–5  years) with a range 
from 3  months to 11  years [48]. In contrast to the dog, 
flea-bite hypersensitivity and environmentally induced 
and AFR look much more similar in the cat [32].
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Diagnosis
A differential diagnosis of AD is based on age of onset, 
breed and clinical signs. Other differential diagnoses 
such as ectoparasites and flea bite hypersensitivity must 
be ruled out by a consequent ectoparasite control. There 
is no single test differentiating the atopic from the non-
atopic dog or cat [49].
It is not possible to distinguish clinical signs of AD 
caused by perennial environmental allergens from AFR 
[16, 50, 51]. Hence an elimination diet followed by a 
provocation with the original food should be performed 
in any dog or cat with non-seasonal AD [52], particu-
larly those with a long history of pruritus and/or gas-
trointestinal signs [51, 53]. A diet length of 6–8 weeks is 
recommended, as 90% of the dogs with AFR show some 
improvement during this time period [54]. Every food 
can potentially result in an AFR [55]. The most common 
reported causative allergens for canine AFR are beef, 
dairy products, chicken, wheat, and lamb [56]. How-
ever, soy, corn, egg, pork, fish and rice have also been 
reported as offending allergens [56]. The food sources 
most frequently causing AFR in cats were beef, fish, 
and chicken [58]. Wheat, corn, dairy products, lamb, 
egg, barley and rabbit were also reported as offending 
allergens in individual cats. The selection of appropri-
ate protein and carbohydrate sources for an elimination 
diet can be challenging. It is important to use a protein 
and carbohydrate source, which the dog or cat has never 
received before [52], thus a detailed food history needs 
to be obtained by the veterinarian. Multiple studies have 
shown that various commercial special diets with only 
one protein source on their label were contaminated and 
contained substances not listed on the label [57–60]. 
Highly hydrolysed food is an alternative, but some dogs 
allergic to chicken also react to diets containing hydro-
lysed chicken protein [61]. Therefore a home cooked diet 
by the owner is considered as diagnostic gold standard 
[52], where instead of commercial dry or canned food 
the owner purchases one type of meat and one carbo-
hydrate source and prepares those him-/herself for the 
pet. As cats are obligate carnivores, the use of a carbo-
hydrate source is optional in the short term and indeed 
may reduce palatability. Currently there is no reliable 
alternative test for diagnosing food allergy [62]. There is 
Table 3 Clinical features, diagnosis and treatments of atopic dermatitis for small animals
Dog References Cat References
Age Commonly 6 months to 3 years [41] Commonly < 3 years [31, 32]
Clinical symptoms Pruritus Eosinophilic granuloma complex (indolent 
eosinophilic ulcer, eosinophilic granulomas, 
eosinophilic plaques)
[32, 46, 47]
Inflammation (Erythema, self-induced alopecia, 
excoriation) secondary infection
[41, 42] Head and neck pruritus
Miliary dermatitis
Self-induced alopecia
Affected body part Ear pinnae, axillae, ventral abdomen, extremi-
ties, paws, inguinal, lips, perianal region
[42, 43] Head, mouth, neck, abdomen, trunk
Diagnosis Exclusion diagnosis (rule out differential diag-
nosis, compatible history and clinical signs
Exclusion diagnosis (rule out differential diag-
nosis, compatible history and clinical signs
Therapy Allergen contact avoidance [71] Allergen contact avoidance
Specific targeted: Allergen-specific immuno-
therapy
[70, 72–79, 81, 82] Specific targeted: Allergen specific immuno-
therapy
[33]
Untargeted, symptomatic: Untargeted, symptomatic:
 Glucocorticoids [85]  Glucocorticoids
 Ciclosporin [86, 87, 89]  Ciclosporin [88, 90, 91]
 Oclacitinib [92–95]  Oclacitinib [96]
 Lokivetmab [83, 84]
 Antihistamines [97–100, 103–105]  Antihistamines [33, 106]
Topical: Topical:
 Shampoos [113, 114] [110]
 Hydrocortisone-aceponate [108, 109]  Hydrocortisone-aceponate
 Tacrolimus [111, 112]
Supportive dietary 
interventions
Essential fatty acids [116–119] Essential fatty acids [115]
Probiotics [124, 125]
Cholecalciferol [129]
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only poor correlation between IgE- and IgG-antibodies 
in the serum and clinical food reactions [53, 63]. A patch 
test can be used for the selection of the elimination diet 
food source if the food history is unknown. This test has 
a poor positive predictability, but a high negative predict-
ability [53]. A lymphocyte proliferation test was able to 
detect a type IV hypersensitivity in the blood [64–66] by 
measuring activated T-helper lymphocytes under food 
allergen stimulation with flow-cytometry [66]. In 49 of 54 
AFR dogs this test accurately provided positive reactions 
against one or more food allergens [66], however this test 
is not commercially available at this time.
AD in animals is diagnosed by history, clinical exami-
nation and exclusion of all differential diagnoses. Posi-
tive reactions are frequently seen in healthy dogs on both 
intradermal tests [67] and serum tests for allergen-spe-
cific IgE [68]. The total serum IgE concentrations seem 
to have no clinical relevance in the dog [44]. Once AD is 
diagnosed in an animal, testing can be used in combina-
tion with clinical historical information to choose which 
allergens should be selected for allergen immunotherapy. 
Serum tests for allergen-specific IgE and intradermal 
tests are equally useful and both are still performed with 
allergen extracts in animals, in contrast to component-
resolved tests such as single molecule CAP testing or 
ImmunoCAP ISAC 112 microarray in human medicine 
[45]. Prick puncture testing is not performed routinely in 
veterinary medicine, as intradermal testing is an estab-
lished and safe diagnostic tool with a very low risk of 
adverse effects [69].
Treatment of atopic dermatitis in small animals
Therapy selection depends on the pet’s condition, espe-
cially the severity of the lesions and degree of pruritus 
and owner preference and especially in cats—on the 
ability to medicate. The therapy needs to be reassessed 
regularly and adapted to the individual [70]. With the 
exception of avoidance of the causative allergen [71], in 
general there are two different treatment approaches: 
specific with allergen immunotherapy or symptomatic 
with a variety of drugs. The combination of various drugs 
can increase the chance of remission [70].
Specific allergen‑targeted therapy
Allergen immunotherapy (AIT) is the only possibly cura-
tive treatment option [70]. In approximately 50–75% of 
the atopic animals desensitization is effective [72–76]. In 
those animals, it is often recommended to continue the 
treatment lifelong [70, 77]. In contrast to human medi-
cine where accelerated immunotherapy (“rush”) is only 
advised in selected patients, due to the high frequency of 
systemic adverse reactions, in dogs rush-immunotherapy 
is effective and safe with no reported increased risk of 
adverse reactions [76, 78, 79]. Intralymphatic desensitiza-
tion (ILIT) in humans was reported to reduce the thera-
peutic interval from 3 years to 8 weeks with less severe 
adverse effects [80]. ILIT is also used in veterinary medi-
cine, but with less predictable success than in humans 
and a recent report showed the need for ongoing immu-
notherapy at regular intervals [81]. Sublingual immuno-
therapy (SLIT) was introduced to veterinary medicine 
some years ago, but so far limited published data is avail-
able [82].
Biologicals
Monoclonal antibodies are a focus of research in human 
medicine. They target specific receptors or cytokines and 
are highly specific and effective in blocking their target 
molecule. Lokivetmab is a monoclonal caninised anti-
IL-31 antibody, that was recently approved for the use in 
atopic dogs. It significantly decreased pruritus for at least 
4 weeks [83]. Its efficacy is comparable to oral predniso-
lone. Lokivetmab is regarded as safe without any imme-
diate hypersensitivity reactions. Adverse reactions were 
similar in dogs treated with lokivetmab to those treated 
with placebo [84]. In the treatment group, 2.5% of the 
dogs produced antibodies against lokivetmab [84] but 
their clinical significance is unclear at this point. To date 
no other therapeutic monoclonal antibody exists in vet-
erinary medicine.
General anti‑inflammatory and anti‑pruritic treatment
In severely affected dogs and cats, glucocorticoids, ciclo-
sporin, oclacitinib or lokivetmab are used for symp-
tomatic therapy due to their clinical efficacy and high 
success rates of 70–80% [85].
Glucocorticoids are inexpensive, universally available 
and have been the mainstay of treatment for allergic pets 
for many years. However, the potentially severe adverse 
effects of oral and particularly injectable depot glucocor-
ticoids such as polyuria and polydipsia, polyphagia, mus-
cle atrophy, secondary skin infections, calcinosis cutis 
and others have led to the development of alternative 
drugs for dogs and cats.
Ciclosporin, a calcineurin inhibitor, is highly effective 
in dogs and cats with comparable results to glucocorti-
coids [86–88]. The initial daily dosage can be reduced 
in the majority of animals to every other day or twice 
weekly [86, 87]. Mild gastrointestinal symptoms (e.g. 
diarrhoea and vomiting) frequently occur at the begin-
ning of treatment but usually resolve during continued 
administration [89]. Hirsutism, gingival hyperplasia 
and hyperplastic dermatitis are reported adverse effects 
which typically resolve with dose reduction or discon-
tinuation [87]. Sporadic case reports exist of immuno-
logically naive cats newly infected with Toxoplasma 
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gondii, developing systemic and even fatal clinical signs 
[90, 91]. It is recommended to evaluate anti-toxoplasma 
antibodies in outdoor cats and cats fed raw meat prior 
to initiating cyclosporine therapy.
Oclacitinib is a selective inhibitor of janus kinase 1. 
Janus kinase 1 is involved in the signaling pathways of 
the receptors for IL-2, IL-4, IL-6, IL-13 and IL-31 [92], 
and thus aims at blocking the Th2 pathway. It is admin-
istered to dogs at a dose of 0.4–0.6  mg/kg twice daily 
for 2  weeks and then daily at that dose is reported to 
be as effective as glucocorticoids [93, 94]. In compari-
son to cyclosporine, oclacitinib has a more rapid effect 
and gastrointestinal adverse effects are less frequently 
observed [95]. Skin infections and histiocytomas were 
reported with increased frequency in dogs on longer 
term oclacitinib therapy [93]. Oclacitinib given to a 
small number of cats with atopy-like dermatitis over 
a 4  week period was effective [96], however the dose 
required was higher than for dogs, the period of moni-
toring was short and both more and larger studies are 
needed before it can be recommended as standard 
therapy.
Different antihistamines are associated anecdotally with 
individual responses, therefore a trial therapy with vari-
ous antihistamines over 7–14  days is recommended [97, 
98]. Histamine binds to four receptor subtypes (H1to H4) 
which are expressed in different tissues [99]. Its interaction 
with the high-affinity H1 receptor is known to cause cuta-
neous vasodilatation, oedema, and wheal formation. His-
tamine can also attract effector cells such as eosinophils to 
the region of inflammation [99]. Antihistamines targeting 
the cutaneous H1 receptors block the binding of histamine 
and are used most frequently in order to reduce the pruri-
tus in atopic dogs [100]. Antihistamines binding to the H4 
receptor showed an anti-inflammatory and anti-pruritic 
effect in mice [101, 102]. However, they did not prevent the 
development of acute skin lesions in a canine atopic model 
[103]. A double blinded, placebo-controlled, cross-over 
study evaluated the efficacy of dimetindene and a combi-
nation of hydroxyzine and chlorpheniramine in 19 atopic 
dogs and concluded that in both groups a limited, but sig-
nificant improvement on pruritus was achieved, neverthe-
less other drugs might additionally be needed [104]. Many 
owners consider antihistamines useful therapeutic agents 
for their pets’ allergy [105]. The recommended dosage of 
antihistamines is much higher in cats and dogs than in 
humans. Dogs can rapidly metabolise hydroxyzine to ceti-
rizine and need twice daily hydroxyzine orally at 2.0 mg/kg 
[99]. In one study a positive effect of antihistamines, mainly 
loratadine and cetirizine, was shown in 67% of 31 atopic 
cats [33]. In contrast, in another study, cats with allergic 
dermatitis treated with cetirizine hydrochloride showed 
no significant differences in lesion- and pruritus-scores to 
those treated with placebo [106].
A future non-specific treatment alternative might be the 
subcutaneous injection of cytosine-phosphate guanine oli-
godeoxynucleotides bound to gelatine nanoparticles (CpG 
GNPs). This therapy resulted in decreased lesions and pru-
ritus in ≥ 50% of atopic dogs, similar to what is seen with 
AIT and the mRNA expression of IL-4 was also decreased 
in those dogs [107]. However, this treatment is currently 
not commercially available.
Due to their hair coat and compliance issues, topical 
treatment of dogs and cats can be difficult for owners and 
therefore it is less frequently used than in humans [44]. 
Topical glucocorticoid ointments can be used for localised 
skin lesions in sparsely haired areas, but prolonged applica-
tion may result in skin atrophy [98]. Topical hydrocortisone 
aceponate was effective for canine AD [108, 109] and feline 
atopy-like dermatitis [110]. Topical calcineurin inhibitors 
such as tacrolimus have been used successfully in localized 
lesions of canine AD [111, 112]. Atopic dogs may benefit 
from shampoo therapy [113, 114].
Adding dietary supplementations such as essential fatty 
acids (EFA), probiotics or vitamins can have a positive ben-
efit for atopic animals. EFA are used to treat AD in cats 
[115] and dogs [116]. Oral EFA can improve the coat qual-
ity, strengthen the skin barrier and reduce the transepider-
mal water loss [117]. Moreover EFA can lower the amount 
of glucocorticoids and cyclosporine needed to control clin-
ical signs of canine AD [118, 119].
Probiotics are microorganisms that are claimed to pro-
vide health benefits when consumed [120, 121]. Their 
mechanism is not completely elucidated, but may involve 
binding Toll-like receptors and downregulate the allergic 
predominately TH2-mediated response [122, 123]. Lacto-
bacillus paracasei K71 given orally to atopic dogs led only 
to a slight improvement of lesion- and pruritus-score [124]. 
However, the medication score was reduced significantly 
indicating a potential benefit as a complementary therapy 
[124]. Lactobacillus rhamnosus GG given to puppies led to 
a reduction of immunologic indicators of AD, even though 
no significant clinical improvement was observed [125].
In human studies a positive impact of cholecalciferol on 
AD was detected [126–128]. Similarly, systemic cholecal-
ciferol reduced pruritus and lesion scores in dogs with AD 
[129].
How to diagnose and manage AD in the difficult 
animal and its owner
Both diagnosis and therapy of AD in cats and dogs 
requires patience, time and effort. An appropriate diag-
nostic work-up will ensure the correct diagnosis of the 
disease and concurrent flare factors and usually includes 
an elimination diet and ectoparasite control as well as 
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cutaneous cytology to rule out secondary infections. It 
is not uncommon for dogs and cats with environmen-
tal allergies to be affected by flea bite hypersensitivity or 
AFR concurrently [32, 50] and it can be difficult to deter-
mine how much of the symptomatology is due to which 
type of antigen. In those animals, the diagnostic work-up 
may require an elimination diet with several provocation 
trials and an extensive flea control in addition to repeated 
examinations of the animal in order to ensure adequate 
resolution of secondary infections and concurrent flea 
bite hypersensitivity. Many owners do not believe that 
their dog or cats’ problem is food triggered and are reluc-
tant to limit their pet’s food intake to one protein and one 
carbohydrate source. AFR is not necessarily related to a 
recent diet change and in one report most of the dogs 
with AFR received the same food for 2  years or longer 
before symptoms arose [130]. An elimination diet with 
restriction to one food source in outdoor or free-roaming 
cats, dogs living on a farm or in a household with small 
children is difficult to impossible. Cats should ideally be 
kept inside for the diet period [131] and some dogs need 
to wear a muzzle during walks to prevent the rapid gob-
bling down of potentially allergenic food stuff [51, 132]. 
Throughout the diagnostic process owner noncompliance 
can be an issue, because of high costs, continuous drug 
administration and the organisational and emotional 
problems associated with feeding a limited elimination 
diet. Thorough and repeated client education and sup-
port contribute to good owner compliance [133]. A diary 
for the owners to record the daily pruritus, drug side 
effects or pitfalls during the elimination diet can increase 
their motivation [131]. Low palatability, refusal of the diet 
(particularly in cats) or gastrointestinal symptoms such 
as diarrhoea or constipation can decrease compliance 
[134]. A gradual change to the “new” food can minimise 
those problems. In contrast to dogs it is not an option 
to allow cats to “starve for a few days” while offering the 
new diet, as a negative energy balance due to anorexia 
can initiate hepatic lipidosis [135]. Owners may need 
to be made aware of the “traps” of an elimination diet 
[131], for example tooth paste and medications for pets 
are frequently flavoured with animal proteins and thus 
will interfere with the elimination diet. Chewable drugs 
or drugs in gelatin capsules need to be avoided [131] as 
it was shown that dogs allergic to corn and soy showed 
cutaneous flares after receiving chewable capsules con-
taining pig protein, soy and milbemycin [132]. Similarly 
many owners do not consider treats “food” and rely on 
those for dog training. Those treats need to be replaced 
with one made of the protein used in the diet to optimise 
outcome. Secondary infections, most often Malassezia 
spp. in dogs [117, 136] and staphylococci in dogs and 
cats [137–140] may mimic the clinical signs of allergy 
and require investigation of other possible causes for the 
infection. After establishing the diagnosis, it is important 
to explain to the owner that an allergy is a lifelong dis-
ease and thus will usually require lifelong management. 
Multiple adaptations of therapy may be needed depend-
ing on the individual animal’s condition and flare factors. 
Treatment options, their costs, efficacy and safety need 
to be discussed with the owners in detail. Some may pre-
fer a rapid clinical improvement with a potent systemic 
drug, whereas others may not want to risk this drug’s side 
effects. Short-term relief can lead to a higher owner com-
pliance. The emotional relationship between owner and 
animal should not be underestimated. Often owners suf-
fer with their animal and sleepless nights of the owners 
are the consequence of a highly pruritic animal.
Unmet needs and research
At this point, the pathogenesis of AD in dogs and cats is 
not fully elucidated. Multiple genes are implicated [14]. 
However, further genomic studies and investigations 
on breed differences may allow a better understand-
ing of the heritability. Research on the role of CD25+ 
FoxP3+ T cells is ongoing [20]. In human medicine the 
hygiene hypothesis ascribes the increasing allergy risk to 
a modern environment and life style with less pathogen 
exposure [141, 142]. This might apply to animals in the 
same way as the prevalence of AD seems to be lower in 
dogs living in rural areas [143]. More studies are needed 
to evaluate environmental influence on AD in dogs and 
cats, possibly enabling prophylactic measures in the 
future. Allergen-specific IgE can be measured, but a cor-
relation of the results with clinical signs is not always 
present [144]. Multiple serum allergy tests are offered, 
but cannot be used to diagnose AD. Additionally, inter- 
and intralaboratory variability of some of those tests is 
high [145–148]. With regard to treatment for AD the 
first monoclonal antibody for atopic dogs, an anti-IL-
31-antibody, is available with promising clinical results, 
but the consequences of a long-term blockade of IL-31 
are unknown at this point [84]. Individual phenotypes 
of AD in dogs and cats may respond better to specific 
drugs than others. More studies and pooling of data to 
obtain numbers to achieve significance are needed to 
evaluate the efficacy of specific drugs in specific breeds 
and pheno- as well as genotypes to allow tailored patient-
oriented therapy in veterinary medicine. AIT is typically 
administered via subcutaneous injections in both dogs 
and cats, there is however a lack of well-powered dose-
finding studies in animals. Further and comparative 
studies are also needed to investigate which alternative 
application route is most suitable in which clinical situ-
ation. Using recombinant allergens such as Dermatopha-
goides farinae allergen (Der f 2) [149, 150] may result in 
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more reproducible results and a higher success rate com-
pared to standard AIT and ILIT [151]. Modified aller-
gen preparations such as allergoids, allergen peptides as 
well as alteration with adjuvants may decrease the risk of 
adverse effects and increase efficacy [152]. First studies 
evaluated bacterial oligodeoxynucleotides in canine AD 
[79, 107] with promising results.
Conclusion
AD in pets is diagnosed by history, clinical signs and the 
ruling out of differential diagnoses. Allergy tests (intra-
dermal tests and serum tests for allergen-specific IgE) 
cannot be used as a diagnostic tool for AD, but rather 
in association with clinical history permit the selection 
of relevant allergens for immunotherapy. Multiple flare 
factors such as additional flea-bite hypersensitivity and 
AFR and secondary bacterial or yeast infections can com-
plicate AD in the dog and cat and need to be identified, 
prevented and/or treated. Intensive and regular commu-
nication with the pet owner and a diagnostic work-up 
and treatment tailored to the individual pet and owner’s 
needs is essential for a good compliance and optimal 
outcome.
Abbreviations
AD: atopic dermatitis; Ig: immunoglobulin; IL: interleukin; Th2: T helper 2; 
PO: periostin; AFR: adverse food reaction; AIT: allergen immunotherapy; ILIT: 
intralmyphatic immunotherapy; SLIT: sublingual immunotherapy; EFA: essen-
tial fatty acids; CpG GNPs: cytosine-phosphateguanine oligodeoxynucleotides 
bound to gelatine nanoparticles; Der f 2: Dermatophagoides farinae allergen.
Authors’ contributions
Both authors contributed to writing this paper and reviewing the literature. 
Both authors read and approved the final manuscript.
Acknowledgements
We want to thank the dermatology team of the clinic for their support and 
critical discussion: Dr. Christoph Klinger, Dr. Laura Udraite, Dr. Teresa Boehm 
and Amelie von Voigts-Rhetz. We are grateful to Dr. Sonya Bettenay for the 
revision of the article.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or 
analysed during the current study.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 2 July 2018   Accepted: 10 September 2018
References
 1. Mineshige T, Kamiie J, Sugahara G, Shirota K. A study on periostin 
involvement in the pathophysiology of canine atopic skin. J Vet Med 
Sci. 2018;80(1):103–11.
 2. Marsella R, Girolomoni G. Canine models of atopic dermatitis: a useful 
tool with untapped potential. J Invest Dermatol. 2009;129(10):2351–7.
 3. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol 
Immunopathol. 2006;114(3–4):207–8.
 4. Hillier A, Griffin CE. The ACVD task force on canine atopic derma-
titis (I): incidence and prevalence. Vet Immunol Immunopathol. 
2001;81(3–4):147–51.
 5. Marsella R, Olivry T, Carlotti DN. International Task Force on Canine 
Atopic D. Current evidence of skin barrier dysfunction in human and 
canine atopic dermatitis. Vet Dermatol. 2011;22(3):239–48.
 6. Marsella R, De Benedetto A. Atopic dermatitis in animals and people: an 
update and comparative review. Vet Sci. 2017;4(3):37.
 7. Merryman-Simpson AE, Wood SH, Fretwell N, Jones PG, McLaren WM, 
McEwan NA, et al. Gene (mRNA) expression in canine atopic dermatitis: 
microarray analysis. Vet Dermatol. 2008;19(2):59–66.
 8. Wood SH. The genetics of canine atopic dermatitis [Thesis]: Liverpool; 
2010.
 9. Plager DA, Torres SM, Koch SN, Kita H. Gene transcription abnormalities 
in canine atopic dermatitis and related human eosinophilic allergic 
diseases. Vet Immunol Immunopathol. 2012;149(1–2):136–42.
 10. Schamber P, Schwab-Richards R, Bauersachs S, Mueller RS. Gene expres-
sion in the skin of dogs sensitized to the house dust mite Dermatopha-
goides farinae. G3 (Bethesda). 2014;4(10):1787–95.
 11. Tengvall K, Kierczak M, Bergvall K, Olsson M, Frankowiack M, Farias 
FH, et al. Genome-wide analysis in German shepherd dogs reveals 
association of a locus on CFA 27 with atopic dermatitis. PLoS Genet. 
2013;9(5):e1003475.
 12. Ardesjö-Lundgren B, Tengvall K, Bergvall K, Farias FHG, Wang L, Hed-
hammar A, et al. Comparison of cellular location and expression of Pla-
kophilin-2 in epidermal cells from nonlesional atopic skin and healthy 
skin in German shepherd dogs. Vet Dermatol. 2017;28(4):377-e88.
 13. Shaw SC, Wood JL, Freeman J, Littlewood JD, Hannant D. Estimation of 
heritability of atopic dermatitis in Labrador and Golden Retrievers. Am J 
Vet Res. 2004;65(7):1014–20.
 14. Nuttall T. The genomics revolution: will canine atopic dermatitis be 
predictable and preventable? Vet Dermatol. 2013;24(1):10-8 e3-4.
 15. Verlinden A, Hesta M, Millet S, Janssens GP. Food allergy in dogs and 
cats: a review. Crit Rev Food Sci Nutr. 2006;46(3):259–73.
 16. Picco F, Zini E, Nett C, Naegeli C, Bigler B, Rufenacht S, et al. A prospec-
tive study on canine atopic dermatitis and food-induced allergic 
dermatitis in Switzerland. Vet Dermatol. 2008;19(3):150–5.
 17. Jaeger K, Linek M, Power HT, Bettenay SV, Zabel S, Rosychuk RA, 
et al. Breed and site predispositions of dogs with atopic dermatitis: 
a comparison of five locations in three continents. Vet Dermatol. 
2010;21(1):118–22.
 18. Olivry T, Dean GA, Tompkins MB, Dow JL, Moore PF. Toward a canine 
model of atopic dermatitis: amplification of cytokine-gene transcripts 
in the skin of atopic dogs. Exp Dermatol. 1999;8(3):204–11.
 19. Schlotter YM, Rutten VP, Riemers FM, Knol EF, Willemse T. Lesional skin in 
atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness. 
Vet Immunol Immunopathol. 2011;143(1–2):20–6.
 20. Jassies-van der Lee A, Rutten VP, Bruijn J, Willemse AT, Broere F. CD4+ 
and CD8+ skin-associated T lymphocytes in canine atopic dermatitis 
produce interleukin-13, interleukin-22 and interferon-gamma and 
contain a CD25+ FoxP3+ subset. Vet Dermatol. 2014;25(5):456-e72.
 21. Santoro D, Marsella R, Pucheu-Haston CM, Eisenschenk MN, Nuttall T, 
Bizikova P. Review: pathogenesis of canine atopic dermatitis: skin barrier 
and host-micro-organism interaction. Vet Dermatol. 2015;26(2):84-e25.
 22. Marsella R, Papastavros V, Ahrens K, Santoro D. Decreased expression of 
caspase-14 in an experimental model of canine atopic dermatitis. Vet J. 
2016;209:201–3.
Page 9 of 12Gedon and Mueller  Clin Transl Allergy  (2018) 8:41 
 23. List K, Szabo R, Wertz PW, Segre J, Haudenschild CC, Kim SY, et al. Loss 
of proteolytically processed filaggrin caused by epidermal deletion of 
Matriptase/MT-SP1. J Cell Biol. 2003;163(4):901–10.
 24. Fanton N, Santoro D, Cornegliani L, Marsella R. Increased filaggrin-
metabolizing enzyme activity in atopic skin: a pilot study using a 
canine model of atopic dermatitis. Vet Dermatol. 2017;28(5):479-e111.
 25. Reiter LV, Torres SM, Wertz PW. Characterization and quantification of 
ceramides in the nonlesional skin of canine patients with atopic derma-
titis compared with controls. Vet Dermatol. 2009;20(4):260–6.
 26. Chermprapai S, Broere F, Gooris G, Schlotter YM, Rutten V, Bouwstra 
JA. Altered lipid properties of the stratum corneum in Canine Atopic 
Dermatitis. Biochim Biophys Acta. 2018;1860(2):526–33.
 27. Yoon JS, Nishifuji K, Sasaki A, Ide K, Ishikawa J, Yoshihara T, et al. Altera-
tion of stratum corneum ceramide profiles in spontaneous canine 
model of atopic dermatitis. Exp Dermatol. 2011;20(9):732–6.
 28. Shimada K, Yoon JS, Yoshihara T, Iwasaki T, Nishifuji K. Increased 
transepidermal water loss and decreased ceramide content in lesional 
and non-lesional skin of dogs with atopic dermatitis. Vet Dermatol. 
2009;20(5–6):541–6.
 29. Olivry T, Dunston SM. Expression patterns of superficial epidermal 
adhesion molecules in an experimental dog model of acute atopic 
dermatitis skin lesions. Vet Dermatol. 2015;26(1):53-6, e-17-8.
 30. Reinero CR, DeClue AE, Rabinowitz P. Asthma in humans and cats: is 
there a common sensitivity to aeroallegens in shared environments? 
Environ Res. 2009;109(5):634–40.
 31. Favrot C, Rostaher A, Fischer N. Clinical symptomps, diagnosis 
and therapy of feline allergic dermatitis. Schweiz Arch Tierheilkd. 
2014;156(7):327–35.
 32. Hobi S, Linek M, Marignac G, Olivry T, Beco L, Nett C, et al. Clinical 
characteristics and causes of pruritus in cats: a multicentre study 
on feline hypersensitivity-associated dermatoses. Vet Dermatol. 
2011;22(5):406–13.
 33. Ravens PA, Xu BJ, Vogelnest LJ. Feline atopic dermatitis: a retrospective 
study of 45 cases (2001–2012). Vet Dermatol. 2014;25(2):95-102, e27-8.
 34. Moriello KA. Feline atopy in three littermates. Vet Dermatol. 
2001;12(3):177–81.
 35. Roosje PJ, Whitaker-Menezes D, Goldschmidt MH, Moore PF, Willemse 
T, Murphy GF. Feline atopic dermatitis. A model for Langerhans cell 
participation in disease pathogenesis. Am J Pathol. 1997;151(4):927–32.
 36. Roosje PJ, Dean GA, Willemse T, Rutten VP, Thepen T. Interleukin 
4-producing CD4+ T cells in the skin of cats with allergic dermatitis. Vet 
Pathol. 2002;39(2):228–33.
 37. Diesel A. Cutaneous hypersensitivity dermatoses in the feline patient: a 
review of allergic skin disease in cats. Vet Sci. 2017;4(2):25.
 38. Rodrigues Hoffmann A, Patterson AP, Diesel A, Lawhon SD, Ly HJ, Elkins 
Stephenson C, et al. The skin microbiome in healthy and allergic dogs. 
PLoS ONE. 2014;9(1):e83197.
 39. Meason-Smith C, Diesel A, Patterson AP, Older CE, Johnson TJ, Mansell 
JM, et al. Characterization of the cutaneous mycobiota in healthy 
and allergic cats using next generation sequencing. Vet Dermatol. 
2017;28(1):71-e17.
 40. Szczepanik MP, Wilkolek PM, Adamek LR, Zajac M, Golynski M, Sitkowski 
W, et al. Evaluation of the correlation between Scoring Feline Allergic 
Dermatitis and Feline Extent and Severity Index and skin hydration in 
atopic cats. Vet Dermatol. 2018;29(1):34-e16.
 41. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis 
(XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol 
Immunopathol. 2001;81(3–4):255–69.
 42. Favrot C. Clinical signs and diganosis of canine atopic dermatitis. Eur J 
Companion Anim Pract. 2009;19(3):219–22.
 43. Wilhem S, Kovalik M, Favrot C. Breed-associated phenotypes in canine 
atopic dermatitis. Vet Dermatol. 2011;22(2):143–9.
 44. Pucheu-Haston CM. Atopic dermatitis in the domestic dog. Clin Derma-
tol. 2016;34(2):299–303.
 45. Jensen-Jarolim E, Einhorn L, Herrmann I, Thalhammer JG, Panakova L. 
Pollen allergies in humans and their dogs, cats and horses: differences 
and similarities. Clin Transl Allergy. 2015;5:15.
 46. Diesel A, DeBoer DJ. Serum allergen-specific immunoglobulin E in 
atopic and healthy cats: comparison of a rapid screening immunoassay 
and complete-panel analysis. Vet Dermatol. 2011;22(1):39–45.
 47. Favrot C, Steffan J, Seewald W, Hobi S, Linek M, Marignac G, et al. 
Establishment of diagnostic criteria for feline nonflea-induced hyper-
sensitivity dermatitis. Vet Dermatol. 2012;23(1):45-50, e11.
 48. Bryan J, Frank LA. Food allergy in the cat: a diagnosis by elimination. J 
Feline Med Surg. 2010;12(11):861–6.
 49. DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis 
(XV): fundamental concepts in clinical diagnosis. Vet Immunol Immu-
nopathol. 2001;81(3–4):271–6.
 50. Olivry T, Deboer DJ, Prelaud P, Bensignor E. International task force 
on canine atopic D. Food for thought: pondering the relationship 
between canine atopic dermatitis and cutaneous adverse food reac-
tions. Vet Dermatol. 2007;18(6):390–1.
 51. Hensel P, Santoro D, Favrot C, Hill P, Griffin C. Canine atopic dermatitis: 
detailed guidelines for diagnosis and allergen identification. BMC Vet 
Res. 2015;11:196.
 52. Kennis RA. Food allergies: update of pathogenesis, diagnoses, and 
management. Vet Clin North Am Small Anim Pract. 2006;36(1):175-
84, vii-viii.
 53. Bethlehem S, Bexley J, Mueller RS. Patch testing and allergen-specific 
serum IgE and IgG antibodies in the diagnosis of canine adverse food 
reactions. Vet Immunol Immunopathol. 2012;145(3–4):582–9.
 54. Olivry T, Mueller RS, Prelaud P. Critically appraised topic on adverse 
food reactions of companion animals (1): duration of elimination 
diets. BMC Vet Res. 2015;11:225.
 55. Martin A, Sierra MP, Gonzalez JL, Arevalo MA. Identification of 
allergens responsible for canine cutaneous adverse food reactions to 
lamb, beef and cow’s milk. Vet Dermatol. 2004;15(6):349–56.
 56. Mueller RS, Olivry T, Prelaud P. Critically appraised topic on adverse 
food reactions of companion animals (2): common food allergen 
sources in dogs and cats. BMC Vet Res. 2016;12:9.
 57. Raditic DM, Remillard RL, Tater KC. ELISA testing for common food 
antigens in four dry dog foods used in dietary elimination trials. J 
Anim Physiol Anim Nutr (Berl). 2011;95(1):90–7.
 58. Ricci R, Granato A, Vascellari M, Boscarato M, Palagiano C, Andri-
ghetto I, et al. Identification of undeclared sources of animal origin 
in canine dry foods used in dietary elimination trials. J Anim Physiol 
Anim Nutr (Berl). 2013;97(Suppl 1):32–8.
 59. Willis-Mahn C, Remillard R, Tater K. ELISA testing for soy antigens in 
dry dog foods used in dietary elimination trials. J Am Anim Hosp 
Assoc. 2014;50(6):383–9.
 60. Horvath-Ungerboeck C, Widmann K, Handl S. Detection of DNA from 
undeclared animal species in commercial elimination diets for dogs 
using PCR. Vet Dermatol. 2017;28(4):373-e86.
 61. Jackson HA, Jackson MW, Coblentz L, Hammerberg B. Evaluation of 
the clinical and allergen specific serum immunoglobulin E responses 
to oral challenge with cornstarch, corn, soy and a soy hydro-
lysate diet in dogs with spontaneous food allergy. Vet Dermatol. 
2003;14(4):181–7.
 62. Mueller RS, Olivry T. Critically appraised topic on adverse food 
reactions of companion animals (4): can we diagnose adverse food 
reactions in dogs and cats with in vivo or in vitro tests? BMC Vet Res. 
2017;13(1):275.
 63. Jeffers J, Shanley K, Meyer E. Diagnostic testing of dogs for food hyper-
sensitivity. J Am Vet Med Assoc. 1991;198:245–50.
 64. Fujimura M, Masuda K, Hayashiya M, Okayama T. Flow cytometric analy-
sis of lymphocyte proliferative responses to food allergens in dogs with 
food allergy. J Vet Med Sci. 2011;73(10):1309–17.
 65. Okayama T, Matsuno Y, Yasuda N, Tsukui T, Suzuta Y, Koyanagi M, et al. 
Establishment of a quantitative ELISA for the measurement of allergen-
specific IgE in dogs using anti-IgE antibody cross-reactive to mouse 
and dog IgE. Vet Immunol Immunopathol. 2011;139(2–4):99–106.
 66. Suto A, Suto Y, Onohara N, Tomizawa Y, Yamamoto-Sugawara Y, 
Okayama T, et al. Food allergens inducing a lymphocyte-mediated 
immunological reaction in canine atopic-like dermatitis. J Vet Med Sci. 
2015;77(2):251–4.
 67. Mueller RS, Fieseler KV, Rosychuk RA, Greenwalt T. Intradermal 
testing with the storage mite Tyrophagus putrescentiae in normal 
dogs and dogs with atopic dermatitis in Colorado. Vet Dermatol. 
2005;16(1):27–31.
 68. Lian TM, Halliwell RE. Allergen-specific IgE and IgGd antibodies in atopic 
and normal dogs. Vet Immunol Immunopathol. 1998;66(3–4):203–23.
Page 10 of 12Gedon and Mueller  Clin Transl Allergy  (2018) 8:41 
 69. Hillier A, DeBoer DJ. The ACVD task force on canine atopic der-
matitis (XVII): intradermal testing. Vet Immunol Immunopathol. 
2001;81(3–4):289–304.
 70. Saridomichelakis MN, Olivry T. An update on the treatment of canine 
atopic dermatitis. Vet J. 2016;207:29–37.
 71. Olivry T, Mueller RS. International task force on canine atopic D. 
Evidence-based veterinary dermatology: a systematic review of 
the pharmacotherapy of canine atopic dermatitis. Vet Dermatol. 
2003;14(3):121–46.
 72. Loewenstein C, Mueller RS. A review of allergen-specific immunother-
apy in human and veterinary medicine. Vet Dermatol. 2009;20(2):84–98.
 73. Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an 
effective and safe alternative route for canine atopic dermatitis. Schweiz 
Arch Tierheilkd. 2016;158(9):646–52.
 74. Willemse A, Van den Brom WE, Rijnberk A. Effect of hyposensitization on 
atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184(10):1277–80.
 75. Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-
specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 
2006;158(3):81–5.
 76. Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with 
alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax 
Ausg K Kleintiere Heimtiere. 2014;42(3):167–73.
 77. Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis 
(XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 
2001;81(3–4):363–83.
 78. Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated 
course of injections of allergen extracts (rush immunotherapy) 
for the treatment of dogs with atopic dermatitis. Am J Vet Res. 
2001;62(3):307–10.
 79. Mueller RS, Veir J, Fieseler KV, Dow SW. Use of immunostimulatory 
liposome-nucleic acid complexes in allergen-specific immunotherapy 
of dogs with refractory atopic dermatitis—a pilot study. Vet Dermatol. 
2005;16(1):61–8.
 80. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr 
Opin Allergy Clin Immunol. 2009;9(6):537–43.
 81. Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralym-
phatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol. 
2018;29(2):123-e49.
 82. DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological 
responses of dust mite sensitive, atopic dogs to treatment with sublin-
gual immunotherapy (SLIT). Vet Dermatol. 2016;27(2):82-7e23.
 83. Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers 
JD, et al. A blinded, randomized, placebo-controlled, dose determina-
tion trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 
monoclonal antibody in client owned dogs with atopic dermatitis. Vet 
Dermatol. 2016;27(6):478-e129.
 84. Michels GM, Walsh KF, Kryda KA, Mahabir SP, Walters RR, Hoevers JD, 
et al. A blinded, randomized, placebo-controlled trial of the safety of 
lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal 
antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 
2016;27(6):505-e136.
 85. Olivry T, Foster AP, Mueller RS, McEwan NA, Chesney C, Williams HC. 
Interventions for atopic dermatitis in dogs: a systematic review of 
randomized controlled trials. Vet Dermatol. 2010;21(1):4–22.
 86. Steffan J, Parks C, Seewald W. North American Veterinary Dermatology 
Cyclosporine Study G. Clinical trial evaluating the efficacy and safety 
of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc. 
2005;226(11):1855–63.
 87. Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treat-
ment: long-term safety of ciclosporin in canine atopic dermatitis. Vet 
Rec. 2014;174(Suppl 2):3–12.
 88. Roberts ES, Speranza C, Friberg C, Griffin C, Steffan J, Roycroft L, et al. 
Confirmatory field study for the evaluation of ciclosporin at a target 
dose of 7.0 mg/kg (3.2 mg/lb) in the control of feline hypersensitivity 
dermatitis. J Feline Med Surg. 2016;18(11):889–97.
 89. Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in 
veterinary dermatology. Vet J. 2012;193(2):317–25.
 90. Last RD, Suzuki Y, Manning T, Lindsay D, Galipeau L, Whitbread TJ. A case 
of fatal systemic toxoplasmosis in a cat being treated with cyclosporin 
A for feline atopy. Vet Dermatol. 2004;15(3):194–8.
 91. Lappin MR, Roycroft LM. Effect of ciclosporin and methylprednisolone 
acetate on cats previously infected with feline herpesvirus 1. J Feline 
Med Surg. 2015;17(4):353–8.
 92. Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry 
M. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with 
activity against cytokines involved in allergy. J Vet Pharmacol Ther. 
2014;37(4):317–24.
 93. Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, et al. A 
blinded, randomized, placebo-controlled trial of the efficacy and safety 
of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned 
dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-97, e141-2.
 94. Cosgrove SB, Cleaver DM, King VL, Gilmer AR, Daniels AE, Wren JA, et al. 
Long-term compassionate use of oclacitinib in dogs with atopic and 
allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 
2015;26(3):171-9, e35.
 95. Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, ran-
domized clinical trial comparing the efficacy and safety of oclacitinib 
and ciclosporin for the control of atopic dermatitis in client-owned 
dogs. Vet Dermatol. 2015;26(1):23-30, e7-8.
 96. Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, 
nonfood-induced hypersensitivity dermatitis: results of a small prospec-
tive pilot study of client-owned cats. Vet Dermatol. 2015;26(4):235-e52.
 97. DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis 
(XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol. 
2001;81(3–4):323–9.
 98. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. 
Treatment of canine atopic dermatitis: 2015 updated guidelines from 
the International Committee on Allergic Diseases of Animals (ICADA). 
BMC Vet Res. 2015;11:210.
 99. Bizikova P, Papich MG, Olivry T. Hydroxyzine and cetirizine pharmacoki-
netics and pharmacodynamics after oral and intravenous administra-
tion of hydroxyzine to healthy dogs. Vet Dermatol. 2008;19(6):348–57.
 100. Eichenseer M. Klinische Wirkung der Antihistaminika Chlorpheniramin/
Hydroxyzin  (Histacalmine®) und Dimetinden  (Fenistil®) bei atopischen 
Hunden. Munich: Ludwig-Maximilians-University; 2013.
 101. Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, et al. 
Histamine H4 receptor antagonism reduces hapten-induced scratching 
behaviour but not inflammation. Exp Dermatol. 2009;18(1):57–63.
 102. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, 
Jiang W, et al. A potent and selective histamine H4 receptor 
antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 
2004;309(1):404–13.
 103. Baumer W, Stahl J, Sander K, Petersen LJ, Paps J, Stark H, et al. Lack of 
preventing effect of systemically and topically administered histamine 
H(1) or H(4) receptor antagonists in a dog model of acute atopic der-
matitis. Exp Dermatol. 2011;20(7):577–81.
 104. Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and 
hydroxyzine/chlorpheniramine in atopic dogs: a randomised, con-
trolled, double-blinded trial. Vet Rec. 2013;173(17):423.
 105. Dell DL, Griffin CE, Thompson LA, Griffies JD. Owner assessment of 
therapeutic interventions for canine atopic dermatitis: a long-term 
retrospective analysis. Vet Dermatol. 2012;23(3):228-e47.
 106. Wildermuth K, Zabel S, Rosychuk RA. The efficacy of cetirizine hydro-
chloride on the pruritus of cats with atopic dermatitis: a randomized, 
double-blind, placebo-controlled, crossover study. Vet Dermatol. 
2013;24(6):576-81, e137-8.
 107. Wagner I, Geh KJ, Hubert M, Winter G, Weber K, Classen J, et al. Prelimi-
nary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides 
bound to gelatine nanoparticles as immunotherapy for canine atopic 
dermatitis. Vet Rec. 2017;181(5):118.
 108. Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, et al. Effi-
cacy of a 0.0584% hydrocortisone aceponate spray in the management 
of canine atopic dermatitis: a randomised, double blind, placebo-
controlled trial. Vet Dermatol. 2009;20(3):191–8.
 109. Nuttall TJ, McEwan NA, Bensignor E, Cornegliani L, Lowenstein C, Reme 
CA. Comparable efficacy of a topical 0.0584% hydrocortisone ace-
ponate spray and oral ciclosporin in treating canine atopic dermatitis. 
Vet Dermatol. 2012;23(1):4-10, e1-2.
 110. Schmidt V, Buckley LM, McEwan NA, Reme CA, Nuttall TJ. Efficacy of a 
0.0584% hydrocortisone aceponate spray in presumed feline allergic 
Page 11 of 12Gedon and Mueller  Clin Transl Allergy  (2018) 8:41 
dermatitis: an open label pilot study. Vet Dermatol. 2012;23(1):11-6, 
e3-4.
 111. Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical 
efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine 
atopic dermatitis: a randomized, double-blinded, placebo-controlled, 
cross-over study. Vet Dermatol. 2004;15(5):294–303.
 112. Bensignor E, Olivry T. Treatment of localized lesions of canine atopic 
dermatitis with tacrolimus ointment: a blinded randomized controlled 
trial. Vet Dermatol. 2005;16(1):52–60.
 113. Loflath A, von Voigts-Rhetz A, Jaeger K, Schmid M, Kuechenhoff H, 
Mueller RS. The efficacy of a commercial shampoo and whirlpooling 
in the treatment of canine pruritus—a double-blinded, randomized, 
placebo-controlled study. Vet Dermatol. 2007;18(6):427–31.
 114. Schilling J, Mueller RS. Double-blinded, placebo-controlled study to 
evaluate an antipruritic shampoo for dogs with allergic pruritus. Vet 
Rec. 2012;171(4):97.
 115. Harvey RG. Effect of varying proportions of evening primrose oil and 
fish oil on cats with crusting dermatosis (‘miliary dermatitis’). Vet Rec. 
1993;133(9):208–11.
 116. Bond R, Lloyd DH. A double-blind comparison of olive oil and a 
combination of evening primrose oil and fish oil in the management of 
canine atopy. Vet Rec. 1992;131(24):558–60.
 117. Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. 
Treatment of canine atopic dermatitis: 2010 clinical practice guidelines 
from the International Task Force on Canine Atopic Dermatitis. Vet 
Dermatol. 2010;21(3):233–48.
 118. Saevik BK, Bergvall K, Holm BR, Saijonmaa-Koulumies LE, Hedhammar 
A, Larsen S, et al. A randomized, controlled study to evaluate the steroid 
sparing effect of essential fatty acid supplementation in the treatment 
of canine atopic dermatitis. Vet Dermatol. 2004;15(3):137–45.
 119. Muller MR, Linek M, Lowenstein C, Rothig A, Doucette K, Thorstensen 
K, et al. Evaluation of cyclosporine-sparing effects of polyunsatu-
rated fatty acids in the treatment of canine atopic dermatitis. Vet J. 
2016;210:77–81.
 120. Ohashi Y, Ushida K. Health-beneficial effects of probiotics: its mode of 
action. Anim Sci J. 2009;80(4):361–71.
 121. Elmadfa I, Klein P, Meyer AL. Immune-stimulating effects of lactic acid 
bacteria in vivo and in vitro. Proc Nutr Soc. 2010;69(3):416–20.
 122. Marsella R, Santoro D, Ahrens K, Thomas AL. Investigation of the effect 
of probiotic exposure on filaggrin expression in an experimental model 
of canine atopic dermatitis. Vet Dermatol. 2013;24(2):260-e57.
 123. de Roock S, van Elk M, van Dijk ME, Timmerman HM, Rijkers GT, Prakken 
BJ, et al. Lactic acid bacteria differ in their ability to induce functional 
regulatory T cells in humans. Clin Exp Allergy. 2010;40(1):103–10.
 124. Ohshima-Terada Y, Higuchi Y, Kumagai T, Hagihara A, Nagata M. Com-
plementary effect of oral administration of Lactobacillus paracasei K71 
on canine atopic dermatitis. Vet Dermatol. 2015;26(5):350-3, e74-5.
 125. Marsella R. Evaluation of Lactobacillus rhamnosus strain GG for the pre-
vention of atopic dermatitis in dogs. Am J Vet Res. 2009;70(6):735–40.
 126. Camargo CA Jr, Manson JE. Vitamin D supplementation and risk of 
infectious disease: no easy answers. Am J Clin Nutr. 2014;99(1):3–4.
 127. Di Filippo P, Scaparrotta A, Rapino D, Cingolani A, Attanasi M, Petrosino 
MI, et al. Vitamin D supplementation modulates the immune system 
and improves atopic dermatitis in children. Int Arch Allergy Immunol. 
2015;166(2):91–6.
 128. Udompataikul M, Huajai S, Chalermchai T, Taweechotipatr M, Kamana-
mool N. The effects of oral vitamin d supplement on atopic dermatitis: 
a clinical trial with staphylococcus aureus colonization determination. J 
Med Assoc Thai. 2015;98(Suppl 9):S23–30.
 129. Klinger CJ, Hobi S, Johansen C, Koch HJ, Weber K, Mueller RS. Vitamin 
D shows in vivo efficacy in a placebo-controlled, double-blinded, 
randomised clinical trial on canine atopic dermatitis. Vet Rec. 
2018;182(14):406.
 130. Day MJ. The canine model of dietary hypersensitivity. Proc Nutr Soc. 
2005;64(4):458–64.
 131. Gaschen FP, Merchant SR. Adverse food reactions in dogs and cats. Vet 
Clin North Am Small Anim Pract. 2011;41(2):361–79.
 132. Jackson HA, Hammerberg B. The clinical and immunological reaction 
to a flavoured monthly oral heartworm prophylactic in 12 dogs with 
spontaneous food allergy. Vet Dermatol. 2002;13(4):218.
 133. Chesney CJ. Food sensitivity in the dog: a quantitative study. J Small 
Anim Pract. 2002;43(5):203–7.
 134. Mueller R, Tsohalis J. Evaluation of serum allergen-specific IgE for 
the diagnosis of food adverse reactions in the dog. Vet Dermatol. 
1998;9:167–71.
 135. Valtolina C, Favier RP. Feline hepatic lipidosis. Vet Clin North Am Small 
Anim Pract. 2017;47(3):683–702.
 136. DeBoer DJ, Marsella R. The ACVD task force on canine atopic dermatitis 
(XII): the relationship of cutaneous infections to the pathogenesis and 
clinical course of canine atopic dermatitis. Vet Immunol Immunopathol. 
2001;81(3–4):239–49.
 137. Simou C, Thoday KL, Forsythe PJ, Hill PB. Adherence of Staphylococ-
cus intermedius to corneocytes of healthy and atopic dogs: effect 
of pyoderma, pruritus score, treatment and gender. Vet Dermatol. 
2005;16(6):385–91.
 138. Wildermuth BE, Griffin CE, Rosenkrantz WS. Feline pyoderma therapy. 
Clin Tech Small Anim Pract. 2006;21(3):150–6.
 139. Fazakerley J, Nuttall T, Sales D, Schmidt V, Carter SD, Hart CA, et al. 
Staphylococcal colonization of mucosal and lesional skin sites in atopic 
and healthy dogs. Vet Dermatol. 2009;20(3):179–84.
 140. Yu HW, Vogelnest LJ. Feline superficial pyoderma: a retrospective study 
of 52 cases (2001–2011). Vet Dermatol. 2012;23(5):448-e86.
 141. Platts-Mills TA. The allergy epidemics: 1870–2010. J Allergy Clin Immu-
nol. 2015;136(1):3–13.
 142. Pali-Schöll I, De Lucia M, Jackson H, Janda J, Mueller RS, Jensen-Jarolim 
E. Comparing immediate-type food allergy in humans and companion 
animals-revealing unmet needs. Allergy. 2017;72(11):1643–56.
 143. Meury S, Molitor V, Doherr MG, Roosje P, Leeb T, Hobi S, et al. Role of 
the environment in the development of canine atopic dermatitis in 
Labrador and golden retrievers. Vet Dermatol. 2011;22(4):327–34.
 144. Pucheu-Haston CM, Bizikova P, Eisenschenk MN, Santoro D, Nuttall 
T, Marsella R. Review: the role of antibodies, autoantigens and food 
allergens in canine atopic dermatitis. Vet Dermatol. 2015;26(2):115-e30.
 145. Patterson AP, Schaeffer DJ, Campbell KL. Reproducibility of a commer-
cial in vitro allergen-specific assay for immunoglobulin E in dogs. Vet 
Re. 2005;157(3):81–5.
 146. Lee KW, Blankenship KD, McCurry ZM, Esch RE, DeBoer DJ, Marsella 
R. Performance characteristics of a monoclonal antibody cocktail-
based ELISA for detection of allergen-specific IgE in dogs and 
comparison with a high affinity IgE receptor-based ELISA. Vet Dermatol. 
2009;20(3):157–64.
 147. Thom N, Favrot C, Failing K, Mueller RS, Neiger R, Linek M. Intra- and 
interlaboratory variability of allergen-specific IgE levels in atopic dogs 
in three different laboratories using the Fc-epsilon receptor testing. Vet 
Immunol Immunopathol. 2010;133(2–4):183–9.
 148. Plant JD, Neradelik MB, Polissar NL, Fadok VA, Scott BA. Agreement 
between allergen-specific IgE assays and ensuing immunotherapy 
recommendations from four commercial laboratories in the USA. Vet 
Dermatol. 2014;25(1):15-e6.
 149. Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated 
Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. 
Vet Dermatol. 2017;28(6):583-e141.
 150. Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive 
efficacy of high-dose recombinant mono-allergen immunotherapy in 
atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 
2. Vet Dermatol. 2017;28(2):183-e40.
 151. Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on 
the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) 
immunotherapy in atopic dogs in Hungary and Switzerland. Vet Der-
matol. 2018;14:1.
 152. DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a 
review. Vet Dermatol. 2017;28(1):25-e6.
 153. Sinke JD, Thepen T, Bihari IC, Rutten VP, Willemse T. Immunophenotyp-
ing of skin-infiltrating T-cell subsets in dogs with atopic dermatitis. Vet 
Immunol Immunopathol. 1997;57(1–2):13–23.
 154. Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 
2015;45(3):566–74.
 155. Olivry T, Mayhew D, Paps JS, Linder KE, Peredo C, Rajpal D, et al. Early 
activation of Th2/Th22 inflammatory and pruritogenic pathways 
in acute canine atopic dermatitis skin lesions. J Invest Dermatol. 
2016;136(10):1961–9.
Page 12 of 12Gedon and Mueller  Clin Transl Allergy  (2018) 8:41 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 156. Lee C-H. Immune regulation in pathophysiology and targeted therapy 
for itch in atopic dermatitis. Dermatol Sin. 2016;34:1–5.
 157. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. 
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 
in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 
2006;118(4):930–7.
 158. Mineshige T, Kamiie J, Sugahara G, Yasuno K, Aihara N, Kawarai S, et al. 
Expression of periostin in normal, atopic, and nonatopic chronically 
inflamed canine skin. Vet Pathol. 2015;52(6):1118–26.
 159. Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura 
Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 
2017;74(23):4293–303.
 160. Sung M, Lee KS, Ha EG, Lee SJ, Kim MA, Lee SW, et al. An association of 
periostin levels with the severity and chronicity of atopic dermatitis in 
children. Pediatr Allergy Immunol. 2017;28(6):543–50.
 161. Olivry T, Hill PB. The ACVD task force on canine atopic dermatitis 
(XVIII): histopathology of skin lesions. Vet Immunol Immunopathol. 
2001;81(3–4):305–9.
 162. Correa da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, 
Czarnowicki T, et al. Patients with atopic dermatitis have attenuated 
and distinct contact hypersensitivity responses to common allergens in 
skin. J Allergy Clin Immunol. 2015;135(3):712–20.
 163. Piloto Valdes L, Gomez Echevarria AH, Valdes Sanchez AF, Ochoa Ochoa 
C, Chong Lopez A, Mier Naranjo G. Atopic dermatitis. Findings of skin 
biopsies. Allergol Immunopathol (Madr). 1990;18(6):321–4.
 164. Santoro D, Rodrigues Hoffmann A. Canine and human atopic dermati-
tis: two faces of the same host-microbe interaction. J Invest Dermatol. 
2016;136(6):1087–9.
 165. Meason-Smith C, Diesel A, Patterson AP, Older CE, Mansell JM, 
Suchodolski JS, et al. What is living on your dog’s skin? Characterization 
of the canine cutaneous mycobiota and fungal dysbiosis in canine 
allergic dermatitis. FEMS Microbiol Ecol. 2015;91(12):v139.
 166. Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the 
skin microbiome in atopic dermatitis: a systematic review. Br J Derma-
tol. 2017;177(5):1272–8.
 167. McCandless EE, Rugg CA, Fici GJ, Messamore JE, Aleo MM, Gonzales 
AJ. Allergen-induced production of IL-31 by canine Th2 cells and 
identification of immune, skin, and neuronal target cells. Vet Immunol 
Immunopathol. 2014;157(1–2):42–8.
 168. Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum 
IL-31 with severity of dermatitis in an experimental model of canine 
atopic dermatitis using beagle dogs. Vet Dermatol. 2018;29(1):69-e28.
 169. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. 
IL-25 augments type 2 immune responses by enhancing the expansion 
and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 
2007;204(8):1837–47.
 170. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces 
IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 
2001;15(6):985–95.
 171. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran 
M. IL-25 in atopic dermatitis: a possible link between inflammation and 
skin barrier dysfunction? J Invest Dermatol. 2011;131(1):150–7.
 172. Asahina R, Nishida H, Kamishina H, Maeda S. Expression of IL-33 
in chronic lesional skin of canine atopic dermatitis. Vet Dermatol. 
2018;29:246-e91.
 173. Bruet V, Lieubeau B, Herve J, Roussel A, Imparato L, Desfontis JC, et al. 
Increased numbers of peripheral blood CD34+ cells in dogs with 
canine atopic dermatitis. Vet Dermatol. 2015;26(3):160-4, e33.
 174. Hauck V, Hugli P, Meli ML, Rostaher A, Fischer N, Hofmann-Lehmann R, 
et al. Increased numbers of FoxP3-expressing CD4+ CD25+ regulatory 
T cells in peripheral blood from dogs with atopic dermatitis and its cor-
relation with disease severity. Vet Dermatol. 2016;27(1):26-e9.
